Volume :
6
Issue :
2
Abstract :
High blood pressure is classified as either primary (essential) high blood pressure or secondary high blood pressure. The target of this study is to assess the efficiency of resveratrol in managing blood pressure in members diagnosed with prehypertension and stage 1 hypertension. The main objectives of this trial are to regulate the BP-lowering actions of resveratrol on systolic, diastolic, and mean arterial BP in members diagnosed with prehypertension and stage 1 hypertension. The outcomes from this study will help to decide the effectiveness of short-term resveratrol treatment in hypertensive patients and connect the gap with regards to the recent preclinical and clinical evidence. The primary results in this study will be BP. Systolic and diastolic BPs will be measured by using a mercury sphygmomanometer twice on patient in a sitting position after a 10-minute rest and with a 15-minute interval. The measurement will be done every week during the intervention period. The mean systolic and diastolic BP will be computed. Mean arterial pressure will be calculated as systolic blood BP plus two times the diastolic BP divided by three [(SBP + 2 × DBP) ÷ 3]. This study will also help in gathering further data with regard to recognizing a therapeutically effectual dose of resveratrol in reducing cardiovascular disease risk factors. Importantly, if a positive outcome is identified, it will provide us with an effectual therapeutic strategy to fight against hypertension and would pave the way for reaching enormous population well-being sake. Pharmacokinetics may have assisted to draw a relation between the plasma bioavailability and the actual physiological effect. In this trial, stage 1-hypertensive patients will be on quality therapy for hypertension as well; therefore, it may not be feasible to understand the standalone effictiveness of resveratrol in lowering BP in these patients.